Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesAptevo Therapeutics Inc

Aptevo Therapeutics Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
1.12 USD -0.12 ( 9.68%)
Last update at 2026-11-09T15:34:00Z
VOLUME
26212
Market Cap
6.03M

Momentum Score

…

Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. The company develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells. Its lead clinical blood cancer candidate is mipletamig that is in Phase 1b/2 clinical trial for the treatment of acute myelogenous leukemia. The company also develops ALG.APV-527, a novel investigational bispecific ADAPTIR candidate that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer, head and neck, colorectal, pancreatic, breast, and other solid tumors; APVO603, a preclinical dual agonist bispecific ADAPTIR candidate to treat multiple solid tumors; APVO442, a preclinical bispecific candidate based on the ADAPTIR-FLEX platform technology for the treatment of multiple solid tumors; and APVO711, a preclinical dual mechanism bispecific ADAPTIR candidate to treat prostate cancer. It has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
1.12
Low
1.22
High
52 Week Price Range
3.80
Low
265.90
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Aptevo Therapeutics, Inc. is a publicly listed biopharmaceutical company that has focused on developing immuno-oncology and immune-modulating biologics, though recent public disclosures are limited. Its long-term growth may depend on clinical progress of lead candidates, successful licensing or partnerships, and access to development capital, and investors may find the company attractive if those catalysts produce positive clinical or commercial outcomes.
Major investment risks include high clinical and regulatory risk, reliance on external funding and partnerships to continue development, limited operating history of commercial products and small-cap stock volatility.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
1.24
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.34M
Debt / Equity
0.27
ROE
-234.61%
Net Debt
-16.99M
ROCE
-124.44%
Diluted EPS TTM
-87.27

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -25.97M -24.13M -18.65M 7.01M -29.41M
Net income -25.97M -24.13M -17.41M 42.67M -27.31M
Selling general administrative 11.77M 10.22M 11.77M 13.87M 14.70M
Gross profit -0.24M -0.35M -0.57M 3.11M 12.29M
Reconciled depreciation 0.24M 0.35M 0.61M 0.90M 1.14M
Ebit -26.31M -24.13M -28.88M -28.64M -22.54M
Ebitda -26.07M -23.78M -28.31M -64.92M -21.40M
Depreciation and amortization 0.24M 0.35M 0.57M -36.28M 1.14M
Operating income -26.31M -24.60M -28.88M -28.64M -21.40M
Other operating expenses 26.31M 24.60M 28.88M 31.75M 33.69M
Interest expense - - - -35.66M 7.06M
Income tax expense - - -1.24M -35.66M -2.10M
Total revenue 0.00M 0.00M 0.00M 3.11M 12.29M
Total operating expenses 26.07M 24.25M 28.88M 31.75M 33.69M
Cost of revenue 0.24M 0.35M 17.11M - -
Total other income expense net 0.34M 0.47M 10.23M 35.66M -8.01M
Discontinued operations - - - 1.01M 0.95M
Net income from continuing ops -25.97M -24.13M -17.62M 7.01M -29.41M
Net income applicable to common shares - - - 8.03M -28.46M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 27.19M 15.59M 24.84M 34.22M 56.60M
Other current assets 1.46M 1.95M 2.16M 0.74M 0.78M
Total liab 9.81M 10.84M 12.62M 16.24M 55.38M
Total stockholder equity 17.38M 4.75M 12.22M 17.97M 1.22M
Other current liab 4.31M 3.15M 3.24M 6.71M 23.09M
Common stock 0.11M 0.08M 0.06M 0.05M 0.05M
Capital stock 0.11M 0.08M 0.06M 0.05M 0.05M
Retained earnings -275.12M -247.58M -223.45M -206.04M -214.06M
Other liab - - - - 15.58M
Other assets - - - - 0.07M
Cash 21.62M 8.71M 16.90M 22.64M 45.04M
Total current liabilities 6.05M 6.21M 7.22M 8.71M 34.76M
Net debt -16.99M -4.08M -11.51M -13.10M -28.33M
Short term debt 0.87M - - 2.00M 11.67M
Short long term debt - - - 2.00M 11.67M
Short long term debt total 4.63M 4.63M 5.40M 9.54M 16.71M
Other stockholder equity 292.38M 252.25M 235.61M 223.96M 215.23M
Property plant equipment - - - 6.76M 3.96M
Total current assets 23.08M 10.66M 19.07M 27.45M 52.57M
Net tangible assets - - - 17.97M 1.22M
Net receivables - - - 2.50M 3.66M
Long term debt - - - 1.46M 3.71M
Inventory - - - 1.57M 3.08M
Accounts payable 0.88M 3.05M 3.98M 3.50M 3.46M
Non currrent assets other - - - - 0.07M
Non current assets total 4.11M 4.93M 5.78M 6.76M 4.03M
Capital lease obligations 4.63M 4.63M 5.40M 6.08M 1.34M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - 0.00M 0.00M -0.03M -0.71M
Change to liabilities - - - -0.39M -1.92M
Total cashflows from investing activities - - - -0.03M -0.71M
Net borrowings - 0.00M -3.47M -12.27M -10.55M
Total cash from financing activities 38.50M 15.60M 6.00M -2.62M 26.16M
Change to operating activities - - - 1.37M 0.56M
Net income -25.97M -24.13M -17.41M 8.03M -28.46M
Change in cash 12.90M -8.19M -5.73M -23.67M 3.77M
Begin period cash flow 8.71M 16.90M 22.64M 46.30M 42.53M
End period cash flow 21.62M 8.71M 16.90M 22.64M 46.30M
Total cash from operating activities -25.59M -23.79M -11.73M -21.02M -21.68M
Issuance of capital stock 37.94M 10.04M 9.78M 6.93M 10.23M
Depreciation 0.24M 0.35M 0.57M 0.90M 1.14M
Dividends paid 1.57M - - - -10.23M
Change to account receivables - - 2.50M 1.16M -1.29M
Sale purchase of stock - - -0.01M - 10.23M
Other cashflows from financing activities 1.57M 5.56M 3.04M 2.72M 26.48M
Change to netincome - - - -32.09M 8.29M
Capital expenditures 0.00M 0.00M 0.00M 0.03M 0.71M
Change in working capital -1.05M -1.08M 2.91M 2.14M -2.65M
Stock based compensation 0.10M 1.07M 2.19M 1.80M 1.64M
Other non cash items 1.09M -1.08M 0.01M -33.90M 6.64M
Free cash flow -25.59M -23.79M -11.73M -21.05M -22.39M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
APVO
Aptevo Therapeutics Inc		 -0.12
9.68%		 1.12 - 3.89 2.70 0.35 0.00 0.39
NVO
Novo Nordisk A/S		 0.47
1.18%		 40.78 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 0.34
0.06%		 547.43 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 8.76
0.97%		 913.11 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Aptevo Therapeutics Inc

Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. The company develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells. Its lead clinical blood cancer candidate is mipletamig that is in Phase 1b/2 clinical trial for the treatment of acute myelogenous leukemia. The company also develops ALG.APV-527, a novel investigational bispecific ADAPTIR candidate that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer, head and neck, colorectal, pancreatic, breast, and other solid tumors; APVO603, a preclinical dual agonist bispecific ADAPTIR candidate to treat multiple solid tumors; APVO442, a preclinical bispecific candidate based on the ADAPTIR-FLEX platform technology for the treatment of multiple solid tumors; and APVO711, a preclinical dual mechanism bispecific ADAPTIR candidate to treat prostate cancer. It has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.

2401 4th Avenue, Seattle, WA, United States, 98121

206 838 0500

https://aptevotherapeutics.com

33

Name Title Year Born
Mr. Marvin L. White Pres, CEO & Director 1962
Mr. Jeffrey G. Lamothe CA Exec. VP & CFO 1966
Dr. Jane A. Gross Ph.D. Chief Scientific Officer 1957
Ms. SoYoung Kwon J.D., LL.M. Sr. VP, Gen. Counsel, Corp. Affairs & HR NA
Dr. Fatih M. Uckun M.D., Ph.D. Chief Clinical Advisor & Consultant NA
Dr. Dirk Huebner M.D. Chief Medical Officer 1963
Ms. Daphne L. Taylor Sr. VP of Fin. 1966
Mr. Marvin L. White President, CEO & Director 1962
Mr. Jeffrey G. Lamothe CA Executive VP & COO 1966
Ms. SoYoung Kwon J.D., LL.M. Senior VP, General Counsel, Business Development & Corporate Affairs 1969

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

GFR
CAD 10.93
+37.83%
MOON
CAD 4.86
+10.20%
HG
CAD 4.43
+9.93%
EPRX
CAD 10.57
+8.86%
NUAG
CAD 8.66
+8.79%
CSU
CAD 3257.60
-7.63%
DIV
CAD 3.85
-5.53%
TOI
CAD 99.00
-5.52%
BSX
CAD 0.82
-4.65%
LMN
CAD 26.79
-4.63%

Equity Sectors*

  • Basic Materials

    +3.88%

  • Communication Services

    -1.14%

  • Consumer Cyclical

    +0.75%

  • Consumer Defensive

    -0.36%

  • Energy

    +2.16%

  • Financial Services

    +1.33%

  • Healthcare

    +1.50%

  • Industrials

    +2.97%

  • Real Estate

    +0.41%

  • Technology

    +1.27%

  • Utilities

    +1.09%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…